Clinical Study

Nrg-Gi005- Phase II/III Study Of Circulating Tumor Dna As A Predictive Biomarker In Adjuvant Chemotherapy In Patients With Stage IIa Colon Cancer (Cobra)

Posted Date: Oct 26, 2020

  • Investigator: Davendra Sohal
  • Specialties: Cancer, Colorectal Cancer, Oncology
  • Type of Study: Drug

The purpose of this study is to compare the rate of ctDNA clearance, and progression free survival in "ctDNA detected" patients treated with or without adjuvant chemotherapy following resection of stage IIA colon cancer


To Be Eligible: Must Have Histologically/Pathologically Confirmed Stage Iia Adenocarcinoma Of The Colon, Ecog 0-1, Complete Gross Resection Of The Tumor, Adequate Organ Function, No Metastatic Disease, No Hx Of Organ Transplant, No Other Malignancy Within 5 Years, No Past Or Active Medical Disorder Or Infection That May Impact Participants Safety Or Ability To Adhere To Study Treatment


Colon Cancer

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.